XenoPort Company Profile (NASDAQ:XNPT)

About XenoPort (NASDAQ:XNPT)

XenoPort logoXenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:XNPT
  • CUSIP: 98411C10
  • Web: www.xenoport.com/
Average Prices:
  • 50 Day Moving Avg: $6.71
  • 200 Day Moving Avg: $5.20
  • 52 Week Range: $3.35 - $7.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.71
  • P/E Growth: 0.00
  • Net Margins: -103.12%
  • Return on Equity: -414.36%
  • Return on Assets: -37.19%
  • Average Volume: 1.64 million shs.
  • Beta: 1.94

Frequently Asked Questions for XenoPort (NASDAQ:XNPT)

What is XenoPort's stock symbol?

XenoPort trades on the NASDAQ under the ticker symbol "XNPT."

How were XenoPort's earnings last quarter?

XenoPort, Inc. (NASDAQ:XNPT) posted its earnings results on Thursday, May, 5th. The company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.02. The firm had revenue of $14.12 million for the quarter, compared to analyst estimates of $14.24 million. XenoPort had a negative return on equity of 414.36% and a negative net margin of 103.12%. The firm's quarterly revenue was up 99.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) EPS. View XenoPort's Earnings History.

Who are some of XenoPort's key competitors?

How do I buy XenoPort stock?

Shares of XenoPort can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XenoPort's stock price today?

One share of XenoPort stock can currently be purchased for approximately $7.02.

MarketBeat Community Rating for XenoPort (NASDAQ XNPT)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about XenoPort and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for XenoPort (NASDAQ:XNPT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for XenoPort (NASDAQ:XNPT)
Price Target History for XenoPort (NASDAQ:XNPT)
Analysts' Ratings History for XenoPort (NASDAQ:XNPT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
5/6/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
1/19/2016Credit Suisse GroupInitiated CoverageUnderperform$4.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for XenoPort (NASDAQ:XNPT)
Earnings by Quarter for XenoPort (NASDAQ:XNPT)
Earnings History by Quarter for XenoPort (NASDAQ XNPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2016Q116($0.21)($0.23)$14.24 million$14.12 millionViewN/AView Earnings Details
2/25/2016Q415($0.31)($0.21)$13.74 million$14.07 millionViewListenView Earnings Details
11/4/2015Q315($0.38)($0.38)$11.77 million$11.40 millionViewN/AView Earnings Details
8/5/2015Q215($0.32)($0.39)$9.77 million$8.60 millionViewN/AView Earnings Details
5/6/2015Q115($0.29)($0.33)$8.50 million$7.10 millionViewN/AView Earnings Details
2/19/2015Q414($0.34)($0.28)$7.10 million$7.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.36)$0.13$6.30 million$31.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.33)($0.31)$4.38 million$5.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.32)($0.36)$3.86 million$3.40 millionViewListenView Earnings Details
2/20/2014Q413($0.45)($0.40)$3.35 million$2.90 millionViewListenView Earnings Details
11/4/2013Q313($0.51)($0.39)$3.03 million$2.52 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.53)($0.51)$1.74 million$2.10 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.43)($0.50)$1.20 million$4.59 millionViewN/AView Earnings Details
3/11/2013Q4 2012($0.42)$0.07$1.02 million$0.49 millionViewN/AView Earnings Details
10/24/2012Q312($0.43)($0.41)$2.26 million$0.40 millionViewN/AView Earnings Details
8/7/2012($0.39)($0.22)ViewN/AView Earnings Details
5/2/2012($0.22)($0.26)ViewN/AView Earnings Details
2/14/2012($0.39)($0.48)ViewN/AView Earnings Details
11/2/2011($0.44)($0.55)ViewN/AView Earnings Details
8/3/2011($0.23)$0.55ViewN/AView Earnings Details
5/5/2011($0.49)($0.49)ViewN/AView Earnings Details
2/16/2011($0.62)($0.47)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for XenoPort (NASDAQ:XNPT)
Current Year EPS Consensus Estimate: $-0.49 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS


Dividend History for XenoPort (NASDAQ:XNPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for XenoPort (NASDAQ:XNPT)
Insider Trades by Quarter for XenoPort (NASDAQ:XNPT)
Institutional Ownership by Quarter for XenoPort (NASDAQ:XNPT)
Insider Trades by Quarter for XenoPort (NASDAQ:XNPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/19/2016James E FlynnInsiderBuy20,973$3.99$83,682.27View SEC Filing  
2/12/2016James E FlynnInsiderBuy4,883,761$3.87$18,900,155.07View SEC Filing  
1/20/2016James E FlynnInsiderBuy346,417$4.09$1,416,845.53View SEC Filing  
9/1/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  
7/15/2015Ronald W BarrettCEOSell12,500$7.20$90,000.00View SEC Filing  
7/13/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  
5/11/2015Wendall WierengaDirectorBuy5,000$5.63$28,150.00View SEC Filing  
12/8/2014Gregory T BatesSVPSell14,166$8.35$118,286.10View SEC Filing  
12/8/2014Ronald W BarrettCEOSell7,015$8.36$58,645.40View SEC Filing  
12/5/2014Gianna M BoskoSVPSell60,000$8.45$507,000.00View SEC Filing  
9/9/2014Gregory T BatesSVPSell5,612$5.26$29,519.12View SEC Filing  
6/3/2014John Gordon FreundDirectorBuy12,500$3.93$49,125.00View SEC Filing  
5/27/2014Cathy FriedmanDirectorBuy2,600$3.92$10,192.00View SEC Filing  
5/23/2014John Gordon FreundDirectorBuy15,000$3.73$55,950.00View SEC Filing  
5/23/2014Ronald W BarrettCEOBuy2,600$3.75$9,750.00View SEC Filing  
5/15/2014Paul BernsDirectorSell2,500$3.66$9,150.00View SEC Filing  
4/24/2014Paul BernsDirectorSell2,500$4.30$10,750.00View SEC Filing  
6/14/2013Gregory T BatesSVPSell7,500$5.35$40,125.00View SEC Filing  
5/22/2013Ernest MarioDirectorBuy20,000$5.49$109,800.00View SEC Filing  
8/9/2012Ernest MarioDirectorBuy10,000$8.50$85,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for XenoPort (NASDAQ:XNPT)
Latest Headlines for XenoPort (NASDAQ:XNPT)
Loading headlines, please wait.



XenoPort (XNPT) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.